vidaza
bristol-myers squibb pharma eeig - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
ibutabs 200 mg
vitabalans oy, fínsko - ibuprofén - 29 - antirheumatica, antiphlogistica, antiuratica
azacitidine betapharm
betapharm arzneimittel gmbh - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - azacitidine betapharm je indikovaný na liečbu dospelých pacientov, ktorí nie sú oprávnené na hematopoetickú kmeňových buniek transplantácia (hsct) s:stredne-2 a s vysokým rizikom myelodysplastic syndrómy (mds) podľa medzinárodného prognostického systému hodnotenia (ipss),chronické myelomonocytic leukémia (cmml) s 10 % na 29 % drene výbuchy bez myeloproliferative ochorenie,akútna myeloidná leukémia (aml) s 20% až 30 % výbuchy a multi-pôvod dysplázia, podľa svetovej zdravotníckej organizácie (who), klasifikácia,boj proti praniu špinavých peňazí s > 30 % dreň výbuchy podľa who klasifikácie.
azacitidine celgene
celgene europe bv - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
nurofen 200 mg
reckitt benckiser (czech republic), spol. s r.o. , Česká republika - ibuprofén - 29 - antirheumatica, antiphlogistica, antiuratica
indometacínový gél 1 %
vulm s.r.o., slovensko - indometacín - 29 - antirheumatica, antiphlogistica, antiuratica
fastum gel
a. menarini industrie farmaceutiche riunite s.r.l., taliansko - ketoprofén - 29 - antirheumatica, antiphlogistica, antiuratica
ketospray 10 %
leram pharmaceuticals s.r.o., Česká republika - ketoprofén - 29 - antirheumatica, antiphlogistica, antiuratica
mig-400
berlin-chemie ag, nemecko - ibuprofén - 29 - antirheumatica, antiphlogistica, antiuratica
pentasa slow release tablets 1 g
ferring-léčiva, a.s., Česká republika - mesalazín - 29 - antirheumatica, antiphlogistica, antiuratica